Insights into pharmacotherapy of malignant glioma in adults (Q37575528)

21 August 2017

1 reference

title

Insights into pharmacotherapy of malignant glioma in adults (English)

1 reference

21 August 2017

0 references

Maurizio Salvati

1

1 reference

21 August 2017

Alessandro D'Elia

series ordinal

2

1 reference

21 August 2017

Anna Isabella Formichella

series ordinal

3

1 reference

21 August 2017

Alessandro Frati

series ordinal

4

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

14

1 reference

21 August 2017

page(s)

2279-2290

1 reference

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Recent developments in the use of chemotherapy in brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Survival of human glioma cells treated with various combination of temozolomide and X-rays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Changing paradigms--an update on the multidisciplinary management of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Clinical relevance of MGMT in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

MGMT: its role in cancer aetiology and cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Is protracted low-dose temozolomide feasible in glioma patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Salvage temozolomide for prior temozolomide responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

New (alternative) temozolomide regimens for the treatment of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Emerging antiangiogenic treatments for gliomas - efficacy and safety issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Microvessel density is a prognostic indicator for patients with astroglial brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Researc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Growth factor receptors signaling in glioblastoma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Genetic pathways to glioblastoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

New developments in the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Chemotherapy of anaplastic oligodendroglial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

Survey of treatment recommendations for anaplastic oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903146910

10.1517/14656560903146910

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference